Topisches gegenüber injiziertem GHK-Cu, Anspruch und Daten abgleichen
GHK-Cu topisch oder Injektion an der Evidenz: warum fast alle humanrelevanten Daten topisch sind, warum die injizierbare Anwendung keine Studie hat und Kupfer-Sicherheitsfragen aufwirft und wie man beide Routen ehrlich liest.
By The PepVise Editorial Team · Reviewed August 7, 2026 · 8 min read
Side-by-side comparisons on PepVise rank by weight of evidence, not by bodybuilding forum consensus. Tier badges on every entry.
How we read the literature
- Evidence tier
- We grade the literature on four tiers, High (replicated RCTs or meta-analyses), Moderate (multiple trials with mixed findings), Low (a single pilot or case series), and Anecdotal (preclinical only, no human data). The tier appears on every compound profile beside the claim it supports.
- Trial stage
- Where a compound sits in the human development pipeline is recorded as Preclinical, Phase 1, Phase 2, or Phase 3+. We pull the current stage from ClinicalTrials.gov and the EU Clinical Trials Register on access date and re-verify quarterly.
- Regulatory status
- We state the FDA posture plainly, approved for indication X, or labeled for research use only, or removed from the 503A list, or investigational under a specific IND. Regulatory status changes; every post carries a review date.
- Where we're uncertain
- Every compound profile closes with a named uncertainty section, the question we can't answer from the current literature, the trial we'd want to see, the effect size we'd treat as a real signal. Uncertainty is not a failure mode here; it's load-bearing.
What readers ask us next.
- Ist topisches oder injizierbares GHK-Cu besser belegt?
- Die topische Anwendung trägt praktisch alle humanrelevante Evidenz, überwiegend aus Labor- und Formulierungsstudien, und GHK-Cu ist ein gut etablierter Kosmetikinhaltsstoff. Die injizierbare Anwendung hat keine kontrollierte Humanstudie, sodass beide Routen nicht durch vergleichbare Evidenz gestützt werden.
- Ist das Injizieren von GHK-Cu sicher?
- Seine injizierbare Sicherheit ist in keiner kontrollierten Humanstudie belegt. Die Injektion wirft zudem ein kupferspezifisches Bedenken auf, weil der Körper Kupfer streng reguliert und überschüssiges Kupfer toxisch ist, und die systemische Zufuhr umgeht die kontrollierte Aufnahme von topischem oder ernährungsbedingtem Kupfer. Es gibt keine Studie zur Charakterisierung dieses Risikos.
- Wird GHK-Cu über die Haut aufgenommen?
- Topische Formulierungs- und Kosmetikliteratur behandelt GHK-Cu als hautaktiven Inhaltsstoff, wobei Laborarbeit für den Hautumbau relevante Signaleffekte beschreibt. Wie viel in einem bestimmten Produkt eindringt, hängt von der Formulierung ab, und die topische Grundlage ist von Behauptungen zur injizierten Anwendung getrennt.
- Warum zählen Vorher-Nachher-Fotos der Injektion nicht als Evidenz?
- Unkontrollierte Fotos sind keine Studienergebnisse. Ihnen fehlen Vergleichsgruppe, Verblindung und standardisierte Messung, und sie können das Peptid nicht von Beleuchtung, Pflegeroutine oder normaler Schwankung trennen. Sie illustrieren Anekdote, nicht Wirksamkeit.
A new Phase 2 trial for any of the ranked compounds. A regulatory action changing FDA status. A published replication failure in an independent lab. Any of those would move entries on this list within a week, with a dated note on what changed.
References cited on this page.
PubMed, ClinicalTrials.gov, and FDA documents only. Secondary sources appear when needed to characterize public discourse, never as a source for a clinical claim.
- [01]Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int 2015;2015:648108
- [02]Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide. Int J Mol Sci 2018
- [03]Pyo HK et al. The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res 2007
- [04]Badenhorst T, Svirskis D, Wu Z. Physicochemical characterization and stability of the copper-binding tripeptide GHK-Cu. Pharm Dev Technol 2016
About The Pepvise Editorial Team
The Pepvise Editorial Team is a small group of researchers and science writers reading the peer-reviewed peptide literature and translating it into calm, cited analysis. We do not sell peptides, recommend peptides, or tell readers what to administer. We describe what has been measured, by whom, at what scale, with what effect size.
Compound reviews are signed off by Dr. Priya Narang, MD, MPH (endocrinologist) and Dr. Marcus Haley, PharmD, BCPS (board-certified clinical pharmacist). Both hold verifiable state-board licenses and have signed editorial-independence letters with us. See the full editorial board →
Adjacent in the literature.
GHK-Cu Before and After: What to Expect From the Evidence
GHK-Cu before-and-after on the evidence: what the skin and hair studies actually measured, why online transformation photos are not trial data, and a realistic view of the timeframes and magnitudes involved.
7 min readEvidence · ExplainerPeptides for Healing: What the Evidence Actually Supports
Peptides for healing on the evidence: which repair-associated peptides have human data, which rest on animal wound-healing models, and why the strongest healing peptide is one most people already know.
9 min readEvidence · ExplainerBPC-157 for Tendon Repair, Literature Review
Inclusion criteria, 8-10 preclinical studies tabulated, the human evidence gap, and an honest assessment of the tendon claims.
12 min readGet the 2026 Peptide Evidence Ledger.
A 12-page PDF summary of where 10 major compounds sit, Preclinical / Human pilot / Phase trial / FDA status. Updated quarterly. Free.
By subscribing, you agree to our Privacy Policy. One calm, cited email a week. Unsubscribe anytime.